Association Between Diabetes Mellitus and Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is strongly associated with diabetes insipidus (20-30% of cases), not diabetes mellitus, though rare cases of concurrent diabetes mellitus have been reported as isolated case reports rather than an established association. 1
Primary Endocrine Manifestation: Diabetes Insipidus
The most common and well-established endocrine disorder in LCH is central diabetes insipidus (CDI), occurring in 20-30% of adult patients with LCH, particularly those with multisystem disease. 1 This results from histiocytic infiltration of the hypothalamic-pituitary axis and can either:
- Present before the LCH diagnosis is established 1, 2, 3
- Manifest many years after initial LCH diagnosis 1
- Serve as the first clinical manifestation of LCH 2, 3
The risk of developing diabetes insipidus is significantly greater in patients with multisystem disease compared to unifocal disease. 1
Diabetes Mellitus: An Uncommon Association
In contrast to diabetes insipidus, diabetes mellitus occurring with LCH is exceptionally rare and documented only in isolated case reports:
- A 2015 case report described pulmonary LCH presenting simultaneously with both central diabetes insipidus and type 2 diabetes mellitus 4
- A 2009 case documented a 13-year-old with multisystem LCH who developed type 1 diabetes mellitus 11 months after chemotherapy cessation, despite normal pancreatic imaging 5
- A 2001 report noted only three previous cases of LCH with both diabetes insipidus and diabetes mellitus in adults 6
These represent case reports rather than an established epidemiologic association, and the pathogenic mechanism remains unclear. 5, 6
Clinical Implications for Evaluation
When evaluating adults with suspected histiocytic neoplasms, baseline and follow-up endocrine evaluation should focus on screening for diabetes insipidus and anterior pituitary deficiencies, not diabetes mellitus: 1
- Morning urine and serum osmolality (to detect diabetes insipidus) 1
- FSH, LH with testosterone (males) or estradiol (females) 1
- Corticotropin with morning cortisol 1
- Thyrotropin and free T4 1
- Prolactin and IGF-1 1
MRI brain with gadolinium contrast should be performed to evaluate for hypothalamic and pituitary stalk lesions, which are present in 50-70% of LCH cases with endocrine involvement. 1
Key Diagnostic Pitfall
The absence of the posterior pituitary bright spot on MRI is a typical finding in patients with central diabetes insipidus from LCH and should prompt consideration of this diagnosis. 4 When CDI is diagnosed, radiologic studies must evaluate for osteolytic skull lesions, as bone involvement occurs in 60% of LCH cases and skull lesions place the hypothalamic-pituitary axis at risk. 1, 2
Permanent Consequences
Diabetes insipidus is the most common permanent endocrinopathy in LCH and often persists despite treatment of the underlying disease. 1 Anterior pituitary deficiencies typically correlate with the presence of diabetes insipidus and can occur years after LCH diagnosis. 1 Patients with permanent consequences including diabetes insipidus have significantly higher reactivation rates (62.5% versus 3.1%, p<0.001), necessitating longer follow-up. 7